Lessons of the Ban on Phenylpropanolamine(PPA)
- VernacularTitle:苯丙醇胺事件的启示
- Author:
Huiji QIN
- Publication Type:Journal Article
- Keywords:
Phenylpropanolamine(PPA);
Cerebral hemorrhage;
Adverse drug reaction;
Drug utilization;
Information
- From:
Chinese Journal of Pharmacoepidemiology
2001;10(1):1-3
- CountryChina
- Language:Chinese
-
Abstract:
To help pharmaceutical companies absorb lessons from the Ban on PPA, the article analyses the behavior of SinoUS Smith Kline & French, which led to great loss after the Ban of an PPA by SDA of China. It points out that the Ban of PPA did not come unexpectedly. Before the Ban many clinical reports had been released and the authorities of some countries had already introduced ban on PPA or issued warnings on the possible danger of PPA. If the company in question had taken timely measures to keep track of the information, the loss could have been minimized, It is concluded that the pharmaceutical companies should step up their effort for the monitoring and following-up of their products after introduction of their durgs to markets and attach importance to the study of pharmacoepidemioloy. Pharmaceutical companies should put emphasis on the collection of information.
